Cargando…
Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis
AIM OF THE STUDY: This meta-analysis evaluated serum interleukin-6 (IL-6) levels in hepatocellular carcinoma (HCC) patients compared with healthy controls and hepatitis and cirrhotic patients. MATERIAL AND METHODS: The three databases PubMed, Scopus, and Web of Science were searched for assessment o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185933/ https://www.ncbi.nlm.nih.gov/pubmed/30324143 http://dx.doi.org/10.5114/ceh.2018.78122 |
_version_ | 1783362772006862848 |
---|---|
author | Shakiba, Ebrahim Ramezani, Mazaher Sadeghi, Masoud |
author_facet | Shakiba, Ebrahim Ramezani, Mazaher Sadeghi, Masoud |
author_sort | Shakiba, Ebrahim |
collection | PubMed |
description | AIM OF THE STUDY: This meta-analysis evaluated serum interleukin-6 (IL-6) levels in hepatocellular carcinoma (HCC) patients compared with healthy controls and hepatitis and cirrhotic patients. MATERIAL AND METHODS: The three databases PubMed, Scopus, and Web of Science were searched for assessment of IL-6 levels in HCC patients (without cirrhosis and hepatitis) compared with healthy controls (without HCC, cirrhosis and hepatitis) and the studies were selected based on inclusion and exclusion criteria. A random-effect meta-analysis was performed with RevMan 5.3 software, using mean difference (MD) and 95% confidence intervals (CIs). RESULTS: Out of 503 studies searched in databases, 18 studies were included in the meta-analysis. The pooled analysis with continuous data demonstrated that the IL-6 level in HCC patients was significantly higher than that in healthy controls (MD = 12.44; 95% CI: 9.02-15.85; p < 0.00001). Also, the pooled analysis demonstrated that the IL-6 levels in cirrhotic patients (MD = –6.98; 95% CI: –12.91-1.05; p < 0.02) and patients with hepatitis (MD = –8.43; 95% CI: –11.91-4.95; p < 0.00001) were significantly lower than the level in HCC patients, and the subgroup analyses had high heterogeneity. CONCLUSIONS: The elevated IL-6 levels in HCC patients compared with hepatitis and cirrhosis patients and healthy controls may show a significant association of this cytokine with increased risk of HCC and its potential as a diagnostic marker for HCC in future diagnostic and therapeutic strategies. |
format | Online Article Text |
id | pubmed-6185933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-61859332018-10-15 Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis Shakiba, Ebrahim Ramezani, Mazaher Sadeghi, Masoud Clin Exp Hepatol Original Paper AIM OF THE STUDY: This meta-analysis evaluated serum interleukin-6 (IL-6) levels in hepatocellular carcinoma (HCC) patients compared with healthy controls and hepatitis and cirrhotic patients. MATERIAL AND METHODS: The three databases PubMed, Scopus, and Web of Science were searched for assessment of IL-6 levels in HCC patients (without cirrhosis and hepatitis) compared with healthy controls (without HCC, cirrhosis and hepatitis) and the studies were selected based on inclusion and exclusion criteria. A random-effect meta-analysis was performed with RevMan 5.3 software, using mean difference (MD) and 95% confidence intervals (CIs). RESULTS: Out of 503 studies searched in databases, 18 studies were included in the meta-analysis. The pooled analysis with continuous data demonstrated that the IL-6 level in HCC patients was significantly higher than that in healthy controls (MD = 12.44; 95% CI: 9.02-15.85; p < 0.00001). Also, the pooled analysis demonstrated that the IL-6 levels in cirrhotic patients (MD = –6.98; 95% CI: –12.91-1.05; p < 0.02) and patients with hepatitis (MD = –8.43; 95% CI: –11.91-4.95; p < 0.00001) were significantly lower than the level in HCC patients, and the subgroup analyses had high heterogeneity. CONCLUSIONS: The elevated IL-6 levels in HCC patients compared with hepatitis and cirrhosis patients and healthy controls may show a significant association of this cytokine with increased risk of HCC and its potential as a diagnostic marker for HCC in future diagnostic and therapeutic strategies. Termedia Publishing House 2018-09-10 2018-09 /pmc/articles/PMC6185933/ /pubmed/30324143 http://dx.doi.org/10.5114/ceh.2018.78122 Text en Copyright: © 2018 Clinical and Experimental Hepatology http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Shakiba, Ebrahim Ramezani, Mazaher Sadeghi, Masoud Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title_full | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title_fullStr | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title_full_unstemmed | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title_short | Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
title_sort | evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185933/ https://www.ncbi.nlm.nih.gov/pubmed/30324143 http://dx.doi.org/10.5114/ceh.2018.78122 |
work_keys_str_mv | AT shakibaebrahim evaluationofseruminterleukin6levelsinhepatocellularcarcinomapatientsasystematicreviewandmetaanalysis AT ramezanimazaher evaluationofseruminterleukin6levelsinhepatocellularcarcinomapatientsasystematicreviewandmetaanalysis AT sadeghimasoud evaluationofseruminterleukin6levelsinhepatocellularcarcinomapatientsasystematicreviewandmetaanalysis |